Snowbird Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017


Here are the related meetings in 2018:
Antibodies as Drugs: Translating Molecules into Treatments (C1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (A7)


Organizer(s) Cherié L. Butts, Amy S. Rosenberg, Amy D. Klion and Sachdev S. Sidhu
January 22—26, 2017
Snowbird Resort • Snowbird, Utah USA
Discounted Abstract Deadline: Sep 21, 2016
Abstract Deadline: Oct 20, 2016
Scholarship Deadline: Sep 21, 2016
Discounted Registration Deadline: Nov 21, 2016

Sponsored by Genmab A/S, ImmunoGen, Inc., Merck & Co., Inc., Mersana Therapeutics, Pfizer Inc. and Roche

Summary of Meeting:
The purpose of this meeting is to examine different approaches for treatment of cancer and other diseases (e.g., fibrosis, autoimmunity and inflammatory diseases). The program will provide insights from academic and industry scientists on innovative biologics technologies and treatment strategies for ameliorating disease in an effort to identify synergies and opportunities to cross-fertilize approaches. Furthermore, the meeting includes perspectives from the US Food & Drug Administration and how the outlined strategies will impact the drug review and approval process. The intention is to better inform meeting attendees of current/future strategies for treating disease and best practices for transforming concepts into approved drugs.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, January 22 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 26 with a closing plenary session and keynote address from 17:00 to 19:30, followed by a social hour and entertainment. We recommend return travel on Friday, January 27 in order to fully experience the meeting.

SUNDAY, JANUARY 22

4:00—8:00 PM
Arrival and Registration

Ballroom Lobby
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Ballroom Lobby

MONDAY, JANUARY 23

7:00—8:00 AM
Breakfast

Golden Cliff/Eagles
8:00—9:00 AM
Welcome by the Organizers and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Amy S. Rosenberg, U.S. Food and Drug Administration, USA

Arne Skerra, Technical University of Munich, Germany
Advanced Protein Design Concepts for Biopharmaceutical Drug Discovery and Development: Anticalins and PASylation

9:00—11:15 AM
Modified and Alternative Scaffolds as Novel Biotherapeutics
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Andreas G. Plückthun, University of Zürich, Switzerland

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Engineering Synergistic Innate and Adaptive Cancer Immunotherapy

Coffee Break

Shohei Koide, New York University Langone Medical Center, USA
Controlling Cell Signaling with Designer Binding Proteins

Ken G. Andersson, Royal Institute of Technology, Sweden
Short Talk: Development and Optimization of an E. coli-Based Display Platform for Selection of Affinity Proteins

Takamitsu Hattori, New York University School of Medicine, USA
Short Talk: Antigen Clasping Enables Exceptional Specificity toward Peptides Harboring Post-Translational Modifications

Nina G. Caculitan, Genentech, Inc., USA
Short Talk: The Processing of Antibody Drug Conjugates by Proteases

11:15 AM—5:00 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Superior/Superior Lobby/Wasatch
1:00—10:00 PM
Poster Viewing

Superior/Superior Lobby/Wasatch
4:30—5:00 PM
Coffee Available

Ballroom Lobby
5:00—7:00 PM
Non-Antibody Scaffolds, Microenvironment Modulators
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Amy D. Klion, NIAID, National Institutes of Health, USA

James W. Lillard, Jr., Morehouse School of Medicine, USA
Novel Protein Antagonists Targeting Chemokine Receptors Involved in Cancer and Inflammatory Diseases

John C. Bell, Ottawa Hospital Research Institute, Canada
Virotherapies

Margaret Karow, Akriveia Therapeutics, USA
Optimizing Biologics for Therapeutic Use

Arron Hearn, Abzena plc, UK
Short Talk: A Deimmunised form of the Ribotoxin, Alpha-Sarcin, Lacking CD4+ T Cell Epitopes and its use as an Immunotoxin Warhead

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Superior/Superior Lobby/Wasatch
7:30—10:00 PM
Poster Session 1

Superior/Superior Lobby/Wasatch

TUESDAY, JANUARY 24

7:00—8:00 AM
Breakfast
To encourage networking, particularly among early-career scientists, organizers will be available at reserved tables to discuss specific topics.

Table 1 - Careers in Industry: At and Away from the Bench (Cherié L. Butts)

Golden Cliff/Eagles
8:00—11:30 AM
Enhancing Activity and Tissue-Specific Targeting/Strategies for PK Optimization
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Amy S. Rosenberg, U.S. Food and Drug Administration, USA

Anne S. De Groot, EpiVax, Inc., USA
Novel Methods for Addressing Immunogenicity in Therapeutic Proteins

Nancy M. Dahms, Medical College of Wisconsin, USA
Targeting Muscle Cells

Ashley M. Buckle, Monash University, Australia
Short Talk: Circumventing the Stability-Function Trade-Off in Protein Engineering

Coffee Break

Lynn E. Macdonald, Regeneron Pharmaceuticals, USA
Engineered Mice to Study Novel Antibody and Antibody-Like Molecules

Ruben Boado, ArmaGen, USA
Treatment of Human Lysosomal Storage Disorders with Blood-Brain Barrier Penetrating IgG-fusion Proteins

Andrew D. Baik, Regeneron Pharmaceuticals, USA
Short Talk: Engineering Tissue Specific Delivery of Enzymes for Lysosomal Storage Disease Treatment

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Superior/Superior Lobby/Wasatch
1:00—10:00 PM
Poster Viewing

Superior/Superior Lobby/Wasatch
4:30—5:00 PM
Coffee Available

Ballroom Lobby
5:00—7:00 PM
Bispecific and Antibody-Drug Conjugates
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Cherié L. Butts, Biogen, USA

Jennifer R. Cochran, Stanford University, USA
Designer Multispecific Proteins Based on Natural Ligands

Ariel Munitz, Tel Aviv University, Israel
Targeting ITIM-Bearing Receptors in Mucosal Inflammation

Kisu Kim, Mogam Institute for Biomedical Research, South Korea
Short Talk: Whole IgG Like Bispecific Antibodies Engaging T Cells for Cancer Immunotherapy

Stefan R. Schmidt, Rentschler Biotechnology, Germany
Short Talk: Manufacturing of Complex Biobetters: Half-Life Extended Fusion Proteins and Bispecific Molecules

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Superior/Superior Lobby/Wasatch
7:30—10:00 PM
Poster Session 2

Superior/Superior Lobby/Wasatch

WEDNESDAY, JANUARY 25

7:00—8:00 AM
Breakfast
To encourage networking, particularly among early-career scientists, organizers will be available at reserved tables to discuss specific topics.

Table 1 - Clinical Trial Design: Getting it Right (Amy D. Klion)
Table 2 - Paradigm Shift: Scientist and Entrepreneur (Cherié L. Butts)

Golden Cliff/Eagles
8:00—11:00 AM
Different Approaches to Targeting Tumors: Melanoma as an Example
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* James W. Lillard, Jr., Morehouse School of Medicine, USA

Amy S. Rosenberg, U.S. Food and Drug Administration, USA
Mechanisms for Accelerated Approval, Breakthrough Therapies

Luca Gattinoni, NCI, National Institutes of Health, USA
Harnessing T Memory Stem Cells for Adoptive Cell Transfer Therapy of Cancer

Coffee Break

Pierre Bruhns, Institut Pasteur, France
Microdroplet-Based Massive Kinetic Analyses Reveal Secretion Rate and Affinity from Individual Antibody-Secreting Cells

Réjean Lapointe, University of Montreal, CHUM, Canada
Increasing Complexity in Combining Cancer Immunotherapies

James Torchia, Massachusetts General Hospital, USA
Short Talk: Targeting Lymphoma with Precision using Semisynthetic Anti-Idiotype Peptibodies

11:00 AM—5:00 PM
On Own for Lunch

11:00 AM—1:00 PM
Poster Setup

Superior/Superior Lobby/Wasatch
1:00—10:00 PM
Poster Viewing

Superior/Superior Lobby/Wasatch
4:30—5:00 PM
Coffee Available

Ballroom Lobby
5:00—7:15 PM
Biologics in Autoimmunity/Autoinflammatory Disorders
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Amy D. Klion, NIAID, National Institutes of Health, USA

Virginia Pascual, Cornell University, USA
SLE

Raphaela Theresia Goldbach-Mansky, NIAID, LCID, National Institutes of Health, USA
IL-1-Mediated Autoinflammatory Disorders

Andreas G. Plückthun, University of Zürich, Switzerland
Next-Generation Biologics: Exploiting the Opportunities for Protein Engineering

David P. Humphreys, UCB Pharma, UK, UK
Short Talk: Statistical Design for Effector Function Engineering of Hexameric Fc Domains as a Recombinant IVIG Alternative

Takashi K. Kishimoto, Selecta Biosciences, USA
Short Talk: Developing Biobetters with Improved Efficacy and Safety by Addressing Product Immunogenicity with Tolerogenic Nanoparticles

7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Superior/Superior Lobby/Wasatch
7:30—10:00 PM
Poster Session 3

Superior/Superior Lobby/Wasatch

THURSDAY, JANUARY 26

7:00—8:00 AM
Breakfast
To encourage networking, particularly among early-career scientists, organizers will be available at reserved tables to discuss specific topics.

Table 1 - Careers in Government: At and Away from the Bench (Amy S. Rosenberg)
Table 2 - Academia vs. Government vs. Industry (Cherié L. Butts)

Golden Cliff/Eagles
8:00—11:00 AM
Multimodal Approaches to Allergic Inflammation
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Réjean Lapointe, University of Montreal, CHUM, Canada

Amy D. Klion, NIAID, National Institutes of Health, USA
Eosinophil-Targeted Therapy: Lessons Learned from the Treatment of Hypereosinophilic Syndromes

Bruce S. Bochner, Northwestern University Feinberg School of Medicine, USA
Targeting Siglecs in Allergic Inflammatory Disease

Coffee Break

Hector G. Ortega, GlaxoSmithKline, USA
Blocking Eosinophilic Inflammation with Biologics: Current Experience

Mark P. Waterhouse, University of Leeds, UK
Short Talk: Novel Specific Agents for Blocking IgG-FcgammaRIIIa Interactions

Katharine D. Grugan, Janssen R&D, USA
Short Talk: The Role of Multiple Fc Gamma Receptors in an Antibody Dependent Cellular Phagocytosis Potency Assay

11:00 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Ballroom Lobby
5:00—6:30 PM
Concept to Clinic to Market
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Margaret Karow, Akriveia Therapeutics, USA

Cherié L. Butts, Biogen, USA
Strategies for Transforming Ideas into Viable Drug Candidates

Stylianos Bournazos, Rockefeller University, USA
Optimization of Anti-HIV Antibodies for Prevention and Therapy

Teresa S. Wiley, Wiley Systems, Inc, USA
Short Talk: Steroid Hormone Exposure on Regulation of P53 and Bcl-2: Bio-Mimetic Hormone Replacement Therapy and the Quality of Life for Breast Cancer Patients

6:30—7:15 PM
Closing Keynote Address
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Cherié L. Butts, Biogen, USA

Douglas E. Williams, Codiak Biosciences, USA
Exosomes and Extracellular Vesicles: One Man’s Trash Is Another Man’s Treasure

7:15—7:30 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
7:30—8:30 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Ballroom 1-2
8:30—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Ballroom 1-2

FRIDAY, JANUARY 27

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Genmab A/S ImmunoGen, Inc.
Merck & Co., Inc. Mersana Therapeutics
Pfizer Inc. Roche

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health
National Center for Advancing Translational Sciences (NCATS)

Grant No. 1R13AI126942-01

Funding for this conference was made possible [in part] by 1R13AI126942-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Amgen Inc.


ArmaGen


Biogen


Codiak Biosciences


EpiVax, Inc.


Regeneron Pharmaceuticals, Inc.


Thermo Fisher Scientific Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676